Interview with Martin Nelzow, CEO, Boehringer Ingelheim Brazil
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
Address: Rochaverá Corporate Towers. Av. Nações Unidas, 14.171 – Torre Marble – 18º andar – São Paulo – SP. CEP: 04794-000
Tel: (11) 4949-4700
Web: http://www.boehringer-ingelheim.com.br/principal.asp
The Boehringer Ingelheim group is one of the top 20 pharmaceutical companies in the world. Headquartered in Ingelheim, Germany, operates globally with 138 affiliates in 47 countries and 41,300 employees. Since its founding in 1885, this family business is committed to researching, developing and marketing novel products of high therapeutic value for human and veterinary medicine.
Present in Brazil since 1956, headquartered in Sao Paulo and factory in Itapecerica da Serra (SP), the company employs approximately 1,000 employees and sells products with brands like Anador ®, Bisolvon ®, Buscopan ®, Dulcolax ®, and Mucosolvan ® ® Pharmaton , and several prescription products, with an outstanding performance in the areas respiratory, cardiovascular, Parkinson’s and others.
Located in Itapecerica da Serra, São Paulo, the Brazilian plant has excellence in the manufacture of medicines and is one of the largest and most modern of the group in the world, accounting for the 3rd largest production volume, representing 10% of the company’s global . Through its Industrial Business Area, the plant of Boehringer Ingelheim in Brazil also produces products for other laboratories.
Since 1998, Boehringer Ingelheim has been designated by the Great Place to Work Institute as one of the 100 best companies to work in Brazil. In total, there have been nine nominations, eight of them consecutive. Since 2004 the company has also been designated by the Great Place to Work as one of the best companies to work in Latin America.
Anador ®, Bisolvon ®, Buscopan ®, Dulcolax ®, and Mucosolvan ® ® Pharmaton
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
Fabio Bussinger, partner-director of the Pharmaceutical Institute of Operational Governance (IFGO) in Brazil, documents the market needs that prompted him to set up Benchmarking Operational Competitiveness (BCO) Farma, a long-awaited…
Lauro Moretto, Emeritus President of the Brazilian Academy of Pharmaceutical Sciences and former Executive Vice-President of Sindusfarma provides insights into the main changes that have impacted Brazil’s pharmaceutical field over…
In an exclusive interview, Jarbas Barbosa da Silva, Director-President of the Brazilian Health Regulatory Agency (ANVISA), discusses some of the key specificities of the Brazilian market and highlights some of…
Dr. Wilson Pedreira, executive director of the Oncology and Hematology Center of the Albert Einstein Philanthropic Society in Brazil provides insights into the innovative healthcare model implemented in this cutting…
PharmaBoardroom spoke to Fabrice Chouraqui, President of Novartis Latin America and Canada at the Financial Times LatAm Healthcare & Life Sciences Summit in September 2015. He emphasizes the criticality of…
You’ve made some bold moves in your career – from the head of vaccines in Latin America, followed by stints in Colombia, Puerto Rico, and finally Brazil. What brought you…
We asked Mr. Santos regarding his recommendations to help the government innovate, compete, and grow in the pharmaceutical industry here in Brazil on the Human Genetic Therapies side. Is there…
Many international CROs entered Brazil in the past few years, whereas Quintiles made its first move in Brazil in 1996. What was the strategic decision behind entering Brazil at that…
PGS is a member of ABRACRO, but is in a unique position as both a CRO and a service provider to CROs and pharmaceutical companies. Can you elaborate on the…
The government recently released the ‘BrasilMaior’ plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
The government recently released the BrasilMaior plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
We met recently with Minister Pimentel when he launched his BrasilMaior plan, whose slogan was “Innovate to Compete. Compete to Grow.” If you had to make a recommendation to increase…
See our Cookie Privacy Policy Here
